Fortuna Fix announces Series B financing

Fortuna Fix, a private, UK and Canada-based clinical-stage regenerative medicine company is aiming to be the first to bring to the clinic a patient's own neural stem cells (autologous) produced by direct reprogramming (drNPCs) to replace lost neuronal tissue in neurodegeneration and neurotrauma.

Fortuna today revealed the closing of its $25 million Series B financing. The proceeds will enable the company to conduct Phase I/IIa clinical trials in Parkinson’s disease and spinal cord Injury. Amgen Ventures and other new investors join existing shareholders including Salamander Invest to support the development of Fortuna’s lead programs and its neuro-regenerative technology platforms. In addition to clinical development, the financing will enable further expansion of Fortuna’s automated robotic manufacturing capabilities.

“We are excited to welcome Amgen Ventures and our other investors to Fortuna and I would like to thank them for their strong support for the development of our ethical cell therapies and for their help in bringing our novel regenerative medicine solutions to patients suffering from neurotrauma and neurodegeneration,” says Jan-Eric Ahlfors, chief executive and chief scientific officer of Fortuna. “With Fortuna’s technology platform, there finally exists a tremendous opportunity to deliver autologous drNPCs that can readily replace lost neurons, do not require immune suppression, are ethically sourced, efficacious and address some of the largest unmet medical needs by fixing the underlying pathology of cell loss to enable restoration of functionality in patients,” he added.